U.S. markets closed
  • S&P 500

    4,577.11
    -85.74 (-1.84%)
     
  • Dow 30

    35,368.47
    -543.34 (-1.51%)
     
  • Nasdaq

    14,506.90
    -386.86 (-2.60%)
     
  • Russell 2000

    2,096.23
    -66.23 (-3.06%)
     
  • Crude Oil

    86.15
    +2.33 (+2.78%)
     
  • Gold

    1,813.30
    -3.20 (-0.18%)
     
  • Silver

    23.52
    +0.60 (+2.63%)
     
  • EUR/USD

    1.1328
    -0.0083 (-0.72%)
     
  • 10-Yr Bond

    1.8650
    +0.0930 (+5.25%)
     
  • GBP/USD

    1.3595
    -0.0052 (-0.38%)
     
  • USD/JPY

    114.6020
    +0.0220 (+0.02%)
     
  • BTC-USD

    42,310.30
    +392.66 (+0.94%)
     
  • CMC Crypto 200

    1,007.45
    -1.94 (-0.19%)
     
  • FTSE 100

    7,563.55
    -47.68 (-0.63%)
     
  • Nikkei 225

    28,257.25
    -76.27 (-0.27%)
     

Cassava Sciences faces increased scrutiny of Alzheimer's drug, presses ahead with advanced trials

·5 min read
Cassava Sciences faces increased scrutiny of Alzheimer's drug, presses ahead with advanced trials
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Cassava Sciences is now conducting phase 3 trials for its lead drug candidate, an Alzheimer's treatment called simufilam. Skeptics of the company's research want the FDA to halt those trials to investigate claims of data manipulation. President and CEO Remi Barbier sounded defiant in a recent announcement: "We stand committed to translate what we believe is a promising scientific breakthrough into a potentially meaningful treatment for people with Alzheimer’s disease. The rest is noise.”